Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers

Front Bioeng Biotechnol. 2022 Oct 20:10:1019459. doi: 10.3389/fbioe.2022.1019459. eCollection 2022.

Abstract

Gastrointestinal tumours are the most common solid tumours, with a poor prognosis and remain a major challenge in cancer treatment. Mesenchymal stem cells (MSC) are multipotent stromal cells with the potential to differentiate into multiple cell types. Several studies have shown that MSC-derived exosomes have become essential regulators of intercellular communication in a variety of physiological and pathological processes. Notably, MSC-derived exosomes support or inhibit tumour progression in different cancers through the delivery of proteins, RNA, DNA, and bioactive lipids. Herein, we summarise current advances in MSC-derived exosomes in cancer research, with particular reference to their role in gastrointestinal tumour development. MSC-derived exosomes are expected to be a novel potential strategy for the treatment of gastrointestinal cancers.

Keywords: drug carrier; exosome; gastrointestinal cancer; mesenchymal stem cell; miRNA.

Publication types

  • Review